Black Diamond Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX) announced that its CEO, David M. Epstein, Ph.D., will present an update on the company's progress at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:00 a.m. ET. The presentation will be available via a live webcast through the investor relations section of the company's website, with a replay accessible for 30 days after.

This Cambridge-based company focuses on developing MasterKey therapies targeting undrugged mutations in genetically defined cancers.

News Market Reaction – BDTX

-4.97%

-4.97% Session move

In the trading session that priced this news, BDTX declined 4.97%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the 40^th Annual J.P. Morgan Healthcare Conference being held virtually on Wednesday, January 12, 2022 at 9:00 a.m. ET.

A live webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the presentation will also be available and archived on the site for 30 days.

About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform and drug discovery engine, the Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single therapy that targets a specific family of mutations, termed a MasterKey therapy. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts
For Investors:
Julie Seidel
investors@bdtx.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com

FAQ

When will Black Diamond Therapeutics present at the J.P. Morgan Healthcare Conference?

Black Diamond Therapeutics will present on January 12, 2022, at 9:00 a.m. ET.

Where can I watch the Black Diamond Therapeutics presentation?

You can watch the presentation via a live webcast on the investor relations section of their website.

How long will the Black Diamond Therapeutics presentation be available for replay?

The replay of the presentation will be available for 30 days after the live event.

What is the focus of Black Diamond Therapeutics?

Black Diamond Therapeutics focuses on precision oncology and the development of MasterKey therapies for genetically defined cancers.

What technology does Black Diamond Therapeutics use for drug development?

Black Diamond utilizes the Mutation-Allostery-Pharmacology (MAP) platform for analyzing genetic data and developing therapies.